This board acts as a portal for PVCT investors, and retains the right to refuse service to individuals not in compliance with reasonable, responsible, and intelligible posting practices. Please stay on topic.
...RECENT IN THE NEWS JULY 31 07...
Knoxville lab develops new drug to help destroy cancer
wate.com
PVCT on YouTube...
youtube.com
--------------------------------------------------------------
Letter from the CEO Craig Dee's
The year 2006 was an important one for Provectus Pharmaceuticals. We made significant progress in advancing our lead cancer therapeutic drug Provecta™ for potential use against metastatic melanoma, breast cancer, and liver cancer. Additionally, we were successful advancing our topical hydrogel Xantryl™ for use against acute psoriasis and other chronic dermatologic diseases. We view these two drugs as the backbone of ur Company today, and also a stepping-stone towards further advancement into multiple applications in the future.
Significant milestones reached subsequent to the year-end are as follows:
• On April 24, 2007,we announced successful completion of dosing of the final patient enrolled in our Phase 1 study of Provecta for use on Stage III/IV metastatic melanoma. Current drug therapies for metastatic melanoma include systemic use of interferon-alpha and the chemotherapeutic agent DTIC. Both require repeat dosing over a period of weeks to months or longer, have significant side effects, and have exhibited response rates of less than 20% in clinical trials. We were proud to announce that our preliminary results were several times more efficacious than the existing standard of care and that the drug was well tolerated by our clinical trial patients.
• On February 28, 2007, all outstanding debentures were converted, leaving the Company without any debt on its balance sheet.
• On January 8, 2007, we announced receipt of orphan drug designation for Provecta from the U.S. Food and Drug Administration (FDA) for the treatment of metastatic melanoma.
We remain proud of our accomplishments but acknowledge that the ultimate test for a company in our industry is bringing our therapies through complete regulatory approval and successfully to market. The patience of even the most faithful investors is put to the test during the drug development process. We have made every effort to provide appropriate guidance and deliver on these promises in a timely fashion. It is our dedication to you, our shareholders, that provides our management team with the motivation to move ahead in a timely, yet effective manner. What?s more, as scientists we recognize the severity of the aggressive diseases we are targeting and draw additional purpose from the idea that our products could help thousands of people.
I am quite pleased with our progress in 2006. Furthermore, we believe we are on track to reach our ultimate goals and look forward to another year of achievement. I want to thank our employees, officers and directors for their tireless work this past year. However, I would specially like to thank you for your loyal support. We recognize our obligations to our shareholders, and this is an obligation we intend to fulfill.
Very truly yours,
Craig Dees, Ph.D.
--------------------------------------------------------------
PVCT 6 months chart:
stockcharts.com
Technical analysis:
stockta.com
PVCT News:
finance.yahoo.com
PVCT Video CNBC Europe interview with CEO Craig Dees, Ph.D.
Decembre 23,2005
pvct.com
DETAILED RESEARCH REPORTS:
--------------------------------------------------------------
pvct.com
--------------------------------------------------------------
PVCT insiders transactions:
secform4.com
--------------------------------------------------------------
Drug Delivery Technology magazine special feature article "Revisiting Intralesional Delivery of Cancer Treatment", by Provectus CEO Craig Dees, Ph.D., compares Provectus’ novel cancer drugs to current cancer treatments.
pvct.com
--------------------------------------------------------------
May 17, 2007
Professor Peter Hersey, M.D. comments on PV-10 and a patient's response
Professor Peter Hersey, M.D., a professor of oncology at the University of Newcastle and Medical and Research Director of the Newcastle Melanoma Unit, comments on PV-10 and a patient's response.
Video can be viewed here.
pvct.com
This 15-minute clip follows the progress of an 86-year-old man treated with the drug. Prior to his treatment, his melanoma was so unresponsive to the current standard of care, including numerous invasive operations and toxic chemotherapy, that he was given only months to live.
Video can be viewed here.
pvct.com
--------------------------------------------------------------
Summary of the clinical effects of PV-10 on melanoma
pvct.com
--------------------------------------------------------------
Contact Info
Telephone: +1 (865) 769-4011
Fax: +1 (865) 769-4013
info@pvct.com
Mailing Address:
Provectus Pharmaceuticals, Inc.
7327 Oak Ridge Hwy
Knoxville, TN 37931 USA
Transfer Agent:
(i.e. stockholder records, transfer, change of address, etc.)
Atlas Stock Transfer
5899 South State Street, Suite # 24
Murray, UT 84107
Telephone: +1 (801) 266-7151
Fax: +1 (801) 262-0907
Investor Relations:
Joseph Kessler
The Investor Relations Group
11 Stone St., 3rd fl
New York, NY 10004
Telephone: 212-825-3210
Fax: 212-825-3229
jkessler@investorrelationsgroup.com
Public Relations:
The Investor Relations Group
Janet Vasquez
Telephone: 212-825-3210
janet@theinvestorrelationsgroup.com
Investment Advisor:
Damon Testaverde
Network 1 Financial Securities
Telephone: +1 (800) 205-8031
--------------------------------------------------------------
Share Statistics
Outstanding:
45.45 m
Float:
35.35 m
Non-Corp. Insider Hold'gs:
22.20% (as of 4/1/07)
--------------------------------------------------------------
Company Website
pvct.com |
